Vitamins
8
ACR enhances lung cancer treatment
Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
Most Relevant Research
We explored the potential of acyclic retinoid (ACR), a derivative of vitamin A, in treating lung cancer, particularly focusing on non-small cell lung cancer (NSCLC) and cisplatin-resistant cells. This research is vital because NSCLC is one of the leading causes of cancer-related deaths, and treatments like cisplatin often face challenges due to resistance.
In our study, we observed that ACR can significantly inhibit the EGFR/AKT signaling pathway, which is heavily involved in the progression of lung cancer. We treated human NSCLC A549 cells, as well as cisplatin-resistant A549 (A549CR) cells, with ACR alone and in combination with cisplatin. We assessed various factors including cell viability, apoptosis rates, and the levels of crucial signaling proteins.
The results revealed that ACR not only decreased cell viability but also enhanced the sensitivity of both NSCLC and resistant cells to cisplatin treatment. This suggests that ACR could play an important role in improving therapeutic outcomes for lung cancer patients, especially those who have developed resistance to current treatments.
Our findings indicate that incorporating ACR into treatment regimens may provide an innovative strategy for tackling lung cancer and managing cisplatin resistance, which is a significant hurdle in current cancer therapies.
In our study, we observed that ACR can significantly inhibit the EGFR/AKT signaling pathway, which is heavily involved in the progression of lung cancer. We treated human NSCLC A549 cells, as well as cisplatin-resistant A549 (A549CR) cells, with ACR alone and in combination with cisplatin. We assessed various factors including cell viability, apoptosis rates, and the levels of crucial signaling proteins.
The results revealed that ACR not only decreased cell viability but also enhanced the sensitivity of both NSCLC and resistant cells to cisplatin treatment. This suggests that ACR could play an important role in improving therapeutic outcomes for lung cancer patients, especially those who have developed resistance to current treatments.
Our findings indicate that incorporating ACR into treatment regimens may provide an innovative strategy for tackling lung cancer and managing cisplatin resistance, which is a significant hurdle in current cancer therapies.
9.5
Immune system support
Most Useful Review
I took Mega-Zim to replace the German Wobenzym and found it effective due to its enzyme composition. I consumed 20 tablets daily for 10 days. The enzymes expose lung cancer cells to the immune system, aiding in combating the disease. I always took it before meals with warm water. I'm pleased with the quality and results. I recommend it for anyone in a similar situation.
Iron
9.5
Iron-based multifunctional therapy evaluated
[Construction and in vitro pharmacodynamic evaluation of a polydopamine nanodelivery system co-loaded with gambogic acid, Fe(Ⅲ), and glucose oxidase].
Most Relevant Research
We explored a unique approach to treat lung cancer by developing a multifunctional nanodelivery system that combines several therapeutic methods. This system uses polydopamine as a foundation, with iron ions incorporated into its structure to enhance the therapy's effectiveness.
A notable aspect of our study is that the addition of iron was not just for its own potential benefits. It functioned alongside glucose oxidase and gambogic acid to lead a comprehensive assault on tumor cells. While gambogic acid alone has shown promise, the integration of iron is designed to improve the delivery and efficacy of this treatment.
Under controlled conditions, our system managed to release the therapeutic agents effectively, particularly when stimulated by certain environmental factors like pH changes and near-infrared light. As a result, we observed significant inhibition of tumor proliferation and increased levels of cell death, indicating a potential multi-modal strategy for lung cancer treatment.
Although the study highlights the ability of the iron-enhanced system to contribute to therapy, it's important to recognize that isolating iron's specific effect on lung cancer treatment remains challenging due to the complex interactions involved in this multifunctional approach.
A notable aspect of our study is that the addition of iron was not just for its own potential benefits. It functioned alongside glucose oxidase and gambogic acid to lead a comprehensive assault on tumor cells. While gambogic acid alone has shown promise, the integration of iron is designed to improve the delivery and efficacy of this treatment.
Under controlled conditions, our system managed to release the therapeutic agents effectively, particularly when stimulated by certain environmental factors like pH changes and near-infrared light. As a result, we observed significant inhibition of tumor proliferation and increased levels of cell death, indicating a potential multi-modal strategy for lung cancer treatment.
Although the study highlights the ability of the iron-enhanced system to contribute to therapy, it's important to recognize that isolating iron's specific effect on lung cancer treatment remains challenging due to the complex interactions involved in this multifunctional approach.
8.8
Anemia improvement
Most Useful Review
Anemia improved after my mother, who had her oesophagus removed due to lung cancer, struggled for over three years. Despite trying domestic supplements and iron medications, nothing worked until I started this treatment. Following several months of regular health check-ups, her blood test results showed improvement. I advised others to drink it after meals to avoid stomach ache, and I've noticed a reduction in dizziness. I'm just disappointed it's out of stock now.
Ip 6
9
IP shows potential in lung cancer
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases.
Most Relevant Research
We explored the effects of intrathecal pemetrexed (IP) on lung cancer patients facing leptomeningeal metastases (LM), particularly after they had not responded to previous treatments with EGFR-TKIs. The study analyzed 50 patients who received a 50 mg dose of IP after their cancer progressed, looking closely at their clinical responses and survival outcomes over two years.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
9.5
Preventive effects
Most Useful Review
I have used this for many years; it claims to keep cancer cells at bay, and so far, so good.
Astragalus Root
9.5
Increases energy
Most Useful Review
This Astragalus extract offers me extra energy during my cancer treatments.
8
Supports lung health
Most Useful Review
The Astragalus product is of high quality and beneficial for lung patients and those suffering from fibrosis. It can alleviate symptoms and enhance the body's resilience during lung cancer treatment. However, I believe the dosage should be increased and the size needs to be larger.
Quercetin
9.5
Recommended brand
Most Useful Review
My doctor, a leading oncologist, recommended the Jarrow brand for my treatment for prostate cancer. He stated it is the brand that most accurately reflects its label.
8.8
Reduced cancer pain
Most Useful Review
I chose this quercetin product as it was your number one bestseller. I am using this flavonoid to combat my advanced prostate cancer. The pain in my legs and feet is definitely lessening, which is wonderful. My oncology professor originally predicted I would not survive past early 2020. I’m very pleased with the results from taking this product.
Nattokinase
9.5
Cardiovascular improvement
Most Useful Review
Nattokinase has significantly improved my cardiovascular health. After taking it, I felt more energetic and my blood viscosity seems to have decreased, potentially reducing the risk of lung cancer. This natural alternative to aspirin has no side effects, and I appreciate that it’s safe for long-term use.
9.5
Clot removal effectiveness
Most Useful Review
This product, combined with Serrapeptase, has worked wonders for my blood health issues. After suffering from bilateral pulmonary embolisms, Nattokinase has seemingly helped remove clots and keeps my lungs clear, allowing me to breathe easier, which is crucial for my overall health.
Melatonin
9.5
Apoptosis assistance
Most Useful Review
I take it for cancer purposes, as numerous studies indicate that high dosages (up to 160mg) aid in apoptosis. I recommend increasing the dosage gradually and consulting your doctor about higher amounts, as no side effects were noted.
8.8
Minimising risk
Most Useful Review
I bought this for its potential anti-metastatic properties. Studies suggest that a dose of 20mg per night may reduce the incidence of metastases, particularly in kidney and breast cancer.
Tumeric
9
CU17 enhances Gemcitabine efficacy
Synergistic Anti-Cancer Activities of Curcumin Derivative CU17 Combined with Gemcitabine Against A549 Non-Small-Cell Lung Cancer Cells.
Most Relevant Research
We explored the potential of a curcumin derivative, CU17, in enhancing the effectiveness of Gemcitabine (Gem) against lung cancer. The study examined how this combination therapy affects A549 non-small-cell lung cancer (NSCLC) cells in laboratory settings and in mouse models.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
Our findings revealed that CU17 significantly increased the anti-cancer strength of Gem, leading to better control over cancer cell survival. This was achieved by prolonging the S phase of the cell cycle and inducing G2/M phase arrest, which involved proteins like p21 and p53. Furthermore, CU17 boosted the apoptotic effects of Gem by altering the balance of pro-apoptotic and anti-apoptotic factors.
Additionally, in the in vivo experiments, CU17 not only enhanced the anti-cancer effects of Gem but also reduced its toxicity to vital organs such as the liver, kidneys, and spleen. Overall, our research highlights CU17 as a promising chemosensitizer that could improve treatment outcomes for patients with NSCLC without significantly increasing the side effects of Gem.
9.5
In remission
Most Useful Review
Elizabeth B: Curcumin is known for its anti-cancer properties. I have been taking 2g (4 capsules) daily since shortly after my stage 4 lung cancer diagnosis a year ago. I went into remission within three months, and all my tumours have since disappeared. I have been in remission with no evidence of disease for eight months now.
Ginkgo
9.5
Supports cancer recovery
Most Useful Review
Following a serious head injury, I took Ginkgo biloba sent by a friend from Japan to improve my memory and concentration. I noticed improvements within a few weeks. This supplement has a wide range of health benefits, including fighting lung cancer and boosting metabolism, which is vital for healthy ageing. I feel calmer and more focused, and headaches have diminished significantly. I highly recommend this supplement for enhanced brain function and overall health.
8.8
Cancer treatment benefits
Most Useful Review
The Ginkgo biloba extract has been utilised in traditional Chinese medicine for its benefits to memory and overall well-being. It's effective in treating conditions such as lung cancer and is included in several pharmaceuticals. The extract promotes blood flow to the brain and supports cellular growth, aiding in the prevention and treatment of serious diseases, including cancer. It also improves vascular elasticity and is beneficial in cognitive decline associated with Alzheimer's disease.